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Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are
a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for
advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Patients with stage IIIB or IV chemotherapy-naı ¨ve NSCLC with
EGFR mutation were treated with 250mg gefitinib daily. For mutational analysis, DNA was extracted from paraffin-embedded tissues
and EGFR mutations were analysed by direct sequence of PCR products. Twenty (24%) of the 82 patients analysed had
EGFR mutations (deletions in or near E746-A750, n¼16; L858R, n¼4). Sixteen patients were enrolled and treated with gefitinib.
Twelve patients had objective response and response rate was 75% (95% CI, 48–93%). After a median follow-up of 12.7 months
(range, 3.1–16.8 months), 10 patients demonstrated disease progression, with median progression-free survival of 8.9 months (95%
CI, 6.7–11.1 months). The median overall survival time has not yet been reached. Most of the toxicities were mild. This study showed
that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations.
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Lung cancer has long been the leading cause of cancer death in
North America and became the leading cause of cancer death in
Japan in 1998 (Kuroishi et al, 1999). Both platinum-based and
taxane-based chemotherapy offer modest efficacy and survival
advantages over best supportive care (BSC) alone for chemother-
apy-naı ¨ve patients with advanced non-small cell lung cancer
(NSCLC). Nonetheless, objective response rate (RR) is at most
30–40%, and median survival time (MST) is only 8–10 months
owing to frequent recurrence and metastasis (Non-Small Cell Lung
Cancer Collaborative Group, 1995; Schiller et al, 2002). Other
promising drug therapy has therefore long been awaited.
The epidermal growth factor receptor (EGFR) is a 170kDa
tyrosine kinase (TK) that dimerises and phosphorylates several
tyrosine residues upon binding of several specific ligands. These
phosphorylated tyrosines serve as the binding sites for several
signal transducers that initiate multiple signalling pathways which
lead to cell proliferation, differentiation, migration and metastasis,
angiogenesis and antiapoptosis (Arteaga, 2002). Because EGFR is
highly expressed in 43–89% of NSCLC (Scagliotti et al, 2004),
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib
and erlotinib have emerged as particularly promising target drugs
for treating NSCLC.
Two phase II trials for patients previously treated with
chemotherapy, the Iressa Dose Evaluation in Advanced Lung
Cancer (IDEAL)-1 and -2, revealed favourable objective RRs of
10–20% and a disease control rate of 50% (Fukuoka et al, 2003;
Kris et al, 2003). Subsequent randomised phase III trials were
conducted; the Iressa NSCLC Trial Assessing Combination
Treatment (INTACT)-1 and -2, which were randomised, placebo-
controlled trials of cisplatin/gemcitabine or carboplatin/paclitaxel
with or without gefitinib for chemotherapy-naı ¨ve patients.
However, these did not indicate any additional benefit of gefitinib
over conventional cytotoxic chemotherapy, as measured by RR
and median and 1-year survival (Giaccone et al, 2004; Herbst et al,
2004). Moreover, another phase III trial, the Iressa Survival
Evaluation in Lung Cancer (ISEL), showed no survival benefit of
gefitinib over BSC as a salvage regimen (Thatcher et al, 2005). On
balance therefore, the usefulness of gefitinib for advanced NSCLC
remains controversial. Similar results were observed regarding
another EGFR-TKI, erlotinib (Gatzemeier et al, 2004; Herbst et al,
2005), with the exception of the BR21 trial which showed survival
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sbenefit over BSC for erlotinib as salvage therapy (Shepherd et al,
2005).
Nevertheless, subgroups of patients, such as women, nonsmo-
kers, patients with adenocarcinomas, and East Asian patients, tend
to have higher objective responses and sometimes exhibit dramatic
tumour shrinkage in response to these agents. It would therefore
appear very important to discover biomarkers that predict
gefitinib sensitivity, although EGFR protein expression, the most
plausible candidate marker, does not correlate with gefitinib
efficacy (Cappuzzo et al, 2003).
Recently, activating mutations in the TK domain of EGFR were
reported to be strongly associated with clinical responsiveness
to EGFR-TKIs (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004).
Although these results are thought-provoking, no prospective
trials have been reported to date regarding gefitinib monotherapy
for advanced NSCLC with EGFR mutations. Here, we conducted a
phase II trial to evaluate the efficacy and safety of gefitinib as first-
line therapy for advanced NSCLC with EGFR mutations.
MATERIALS AND METHODS
Study design
This single-arm, phase II clinical trial recruited patients at nine
institutes in north-eastern Japan. This trial consisted of two stages.
First, EGFR mutations in exons 18–21 of the accrued patients were
analysed as described below. In the second stage, only those who
had EGFR mutations were enrolled and treated with gefitinib.
The primary end point was the objective RR to an intervention of
gefitinib administration (250mg daily). Secondary end points were
toxicity and survival.
Patient eligibility
Eligible patients had histologically or cytologically confirmed stage
IIIB or IV, chemotherapy-naı ¨ve NSCLCs with EGFR mutations.
Recurrences after surgical resection were also eligible. Other
eligibility criteria included: (a) age 20 years or older; (b) Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of
0–2; (c) measurable lesions; (d) adequate organ function (i.e.,
leucocyte count X4000mm
 3, haemoglobin X9.5gdl
 1, platelets
X100000mm
 3, total bilirubin p1.5mgdl
 1, AST and ALT p2
times the upper limit of the reference range, serum creatinine
p1.5mg/dl
 1, PaO2 X70torr); and (e) life expectancy of 12 weeks
or longer). Exclusion criteria comprised: (a) unstable angina, acute
myocardial infarction or heart failure within the previous 3
months; (b) uncontrolled diabetes mellitus or hypertension; (c)
active infection; (d) interstitial pneumonia or pulmonary fibrosis
as determined from chest computed tomography (CT); (e)
uncontrolled pleural effusion; (f) active gastrointestinal ulcer; (g)
active metachronous cancer; (h) past history of severe hypersensi-
tivity; (i) severe superior vena cava syndrome; and (j) pregnancy
or breast-feeding. All patients were required to provide written
informed consent. Trial protocol approval was obtained from the
ethics committee or institutional review board (IRB) at each trial
institute.
Treatment plan
Patients received 250mg of gefitinib orally per day. In the event of
unacceptable toxicity (defined as grade 3 or more) or deterioration
of PS to 3 or 4, gefitinib was ceased until this toxicity resolved
and/or PS improved to pgrade 2 within 3 weeks. If this did not
occur, treatment was terminated. In the event of grade 2 or higher
interstitial lung disease (ILD), treatment was also terminated. Dose
reduction was not performed. Treatment was continued unless any
of the following occurred: progressive disease (PD), unacceptable
toxicity (as mentioned above), the study physician decided to
terminate therapy or the patient withdrew consent. No systematic
anticancer treatment, radiotherapy or pleurodesis was permitted
during the trial. Salvage regimens were not restricted for patients
with PD or those leaving the protocol.
Evaluation of efficacy and toxicity
Pretreatment evaluations consisted of the following: complete
medical history, determination of PS, physical examination,
haematologic and biochemical profiles, arterial blood gas exam-
ination, ECG, spirometry, chest X-ray, bone scan, CT of the chest,
ultrasound or CT of the abdomen, and magnetic resonance
imaging or CT of the whole brain. Evaluations performed during
treatment included a weekly chest X-ray, biochemistry, complete
blood count (including platelet and differential leucocyte counts),
physical examination, determination of PS, and toxicity assess-
ment. Moreover, for the early detection of ILD, spirometry and
helical CT scan of the chest were performed once every 2 weeks for
the initial 4 weeks. Imaging studies were scheduled every month to
assess objective response.
Response evaluation criteria in solid tumours (RECIST) guide-
lines were used for evaluation of antitumour activity (Therasse
et al, 2000). Complete response (CR) was defined as the complete
disappearance of all clinically detectable tumours for at least 4
weeks. Partial response (PR) was defined as a X30% decrease in
the sum of the longest diameters of the target lesions for a
minimum of 4 weeks with no new area of malignant disease.
Progressive disease indicated at least a 20% increase in the sum of
the longest diameter of the target lesions or a new malignant
lesion. Stable disease (SD) was defined as insufficient shrinkage
to qualify for PR and insufficient increase to qualify for PD. The
minimum interval to qualify for SD was defined as 8 weeks.
Responses were evaluated by the physician in charge and
confirmed by independent reviewers at an extramural conference.
Toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 2.0. (National
Cancer Institute, 1999).
Mutational analysis of the epidermal growth factor receptor
gene
Tumour specimens were obtained during diagnostic or surgical
procedures. For patients with recurrences after surgical resection,
mutation status was analysed in specimens of the original primary
sites. Biopsied or surgically resected specimens were fixed with
formalin and embedded in paraffin. Whole paraffin-embedded
tissue blocks or X4 slices (5-mm thick) from blocks which were
confirmed by each institute’s pathologist to contain adequate
malignant tumour were sent to First Department of Medicine,
Hokkaido University. Genomic DNA was isolated from specimens
using a DNeasy Tissue kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. For mutational analysis of the
kinase domain of the EGFR, exons 18–21 were amplified with four
pairs of primers as described previously (Paez et al, 2004), using
a HotStarTaq DNA polymerase kit (Qiagen). Polymerase chain
reaction products were purified with a PCR purification kit
(Qiagen) and sequenced directly with an Applied Biosystems
BigDye Terminator kit v3.1 (Applied Biosystems, Foster City, CA,
USA) with an ABI PRISM 310 Genetic Analyzer. Both the forward
and reverse sequences were analysed by BLAST, and chromato-
grams were manually reviewed. If the obtained sequences included
mutation sequences, PCR amplification and sequencing analysis
were repeated to confirm the results. Only the following mutations
described in previous reports (Lynch et al, 2004; Paez et al, 2004;
Pao et al, 2004) were regarded as mutation positive in the present
trial; G719X in exon18, deletions in or near E746-A750 in exon 19,
and L858R and L861Q in exon 21.
First-line gefitinib for NSCLC with EGFR mutations
H Asahina et al
999
British Journal of Cancer (2006) 95(8), 998–1004 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStatistical analysis
Simon’s two-stage minimax design was used to determine the
sample size and decision criteria for this phase II trial (Simon,
1989). With a target activity level of 70% (P1) and minimum RR of
interest set at 30% (P0), we needed 14 evaluable patients to accept
the hypothesis and a 5% significance level to reject it with 90%
power. Assuming an inevaluability rate of p15%, we projected an
accrual of 16 patients. Progression-free survival (PFS) was defined
as the interval between enrolment in this trial and the date of
documented disease progression or death from any cause. Overall
survival (OS) was defined as the interval between enrolment in this
trial and death from any cause. If a patient was lost to follow-up,
that patient was censored at the last date of contact. Median overall
and progression-PFS were estimated by the Kaplan–Meier analysis
method (Kaplan and Meier, 1958). All patients who were enrolled
and treated with gefitinib were included in both efficacy and
toxicity analyses. Data were updated as of 15 June 2006.
RESULTS
Characteristics of patients undergoing epidermal growth
factor receptor mutation analysis
From November 2004 to January 2006, 82 patients underwent
analysis of EGFR mutation status. Patient characteristics are listed
in Table 1. Forty-nine patients (60%) were female. Median age
was 65 years (range, 36–83 years). The most common tumour
histological type was adenocarcinoma in 72 patients (87%). Thirty-
eight patients (46%) were never-smokers. Tissue samples from 44
patients (54%) were obtained by transbronchial biopsy.
Comparison of epidermal growth factor receptor mutation
status and clinicopathological characteristics
Twenty patients (24%) had EGFR mutations (deletions in or near
E746-A750, n¼16; L858R, n¼4). Epidermal growth factor
receptor mutation status and patient clinicopathological charac-
teristics are compared in Table 2. Although no significant
differences were apparent between mutation status and age, sex,
histology or procedure used to obtain tumour specimens, EGFR
mutations were more frequently observed in never-smokers than
in smokers (39 vs 11%, Po0.01).
Response to gefitinib in patients with epidermal growth
factor receptor mutations
Of 20 patients who had EGFR mutations, four were not enrolled to
the subsequent phase II trial. One patient withdrew his consent
before enrolment, one had no appropriate measurable lesions, and
two were misclassified when staging. We therefore excluded these
four patients before enrolment and assembled no more data from
them. Excluding these four patients, 16 patients (median age, 68;
male/female, 3/13; adenocarcinoma/squamous cell carcinoma, 15/
1; current/former/never smokers, 2/1/13) were enrolled in the
phase II trial and treated with gefitinib. Details of EGFR mutations
and clinicopathologic features in patients receiving gefitinib are
described in Table 3. Of the 16 enrolled patients, 12 achieved
objective responses (two CR and 10 PR) with an overall RR of 75%
(95% CI, 48–93%), one (6%) had SD and three (19%) had PD as
the best response. Disease control rate (CRþPRþSD) was 81%
(95% CI, 54–96%). Although the number of L858R patients was
small (n¼3), no significant difference was evident between
type of mutation and RR (exon 19 deletions, 83 vs L858R, 67%;
P¼0.87). To date, only two patients have died, all owing to disease
progression. Of the remaining 14 patients who are still alive, six
maintain PR. Hence, MST has not been reached (Figure 1), and we
instead evaluated median PFS. At the time of this analysis, with
a median follow-up time of 12.7 months, median PFS was 8.9
months (95% CI, 6.7–11.1 months).
Safety and toxicity
Toxicity was evaluated in all eligible patients (Table 4). The most
common manifestations of toxicity were dermatological. One
patient experienced grade 3 rash and terminated gefitinib
treatment on day 81; however, she achieved CR on day 29 and
no recurrence was detected until day 228 without any second-line
treatment for 147 days. Another frequently experienced adverse Table 1 Characteristics of all patients whose tumours were analysed for
EGFR mutations
Characteristics No. of patients (%)
Total no. of patients 82
Age (years)
Median 65
Range 36–83
Sex
Male 33 (40)
Female 49 (60)
Histology
Adenocarcinoma 72 (87)
Squamous cell carcinoma 4 (5)
Large cell carcinoma 3 (4)
Other 3 (4)
Smoking history
Current 28 (34)
Former 16 (20)
Never 38 (46)
Tissue obtained by
Surgery 30 (36)
Transbronchial biopsy 44 (54)
Other biopsies 8 (10)
Abbreviation: EGFR¼epidermal growth factor receptor.
Table 2 Relationship between EGFR mutation status and clinicopatho-
logical characteristics
Mutated Wild type
Characteristics No. of patients (%) No. of patients (%) P
Total no. of patients 20 (24) 62 (76)
Age (range) 67 (36–82) 62 (47-83) 0.10
a
Sex
Male 5 (15) 28 (85) 0.09
b
Female 15 (31) 34 (69)
Histology
Adenocarcinoma 19 (26) 53 (74) 0.24
b
Non-adenocarcinoma 1 (10) 9 (90)
Smoking history
Smoker 5 (11) 39 (89) 0.003
b
Never-smoker 15 (39) 23 (61)
Specimen
Surgery 7 (23) 23 (77) 0.54
b
Biopsy 13 (25) 39 (75)
Abbreviation: EGFR¼epidermal growth factor receptor.
aStudent’s t-test.
bFisher’s
exact test.
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seffect was hepatotoxicity (elevated AST/ALT). One patient
required a long treatment interruption because of grade 3
hepatotoxicity and she discontinued the protocol on day 266. A
further patient experienced grade 3 gastrointestinal ulcer and
grade 4 anaemia and terminated gefitinib treatment on day 56
because of PD.
Interstitial lung disease is the most problematic toxicity in
gefitinib treatment in Japan (Inoue et al, 2003). In the present trial,
one patient experienced grade 1 ILD on day 30, leading to the
termination of gefitinib treatment. This patient was asymptomatic;
ILD was barely detectable on chest X-ray and was recognised only
on chest CT, which revealed a patchy, ground-glass opacity with
centrilobular distribution throughout the lung (Figure 2). This was
assumed to be hypersensitivity-type ILD, and it improved without
steroid administration.
Second-line treatment after disease progression
Of 10 patients who became refractory to gefitinib owing to disease
progression, six received second-line treatment. Two received
carboplatin plus paclitaxel; one had PR and another had PD as
second-line treatment. Another two patients received gemcitabine
plus vinorelbine; one patient had PR and another had PD as
second-line treatment. A further patient terminated gefitinib
monotherapy because of grade 3 hepatotoxicity, recovered after
8 weeks treatment interruption and then resumed gefitinib. The
other patient, in whom PD was diagnosed owing to development of
a new bone metastasis, resumed gefitinib monotherapy after
radiation therapy to the bone metastasis, as his primary and other
lesions were still controlled by gefitinib. The latter two patients
also remained alive at the most recent follow-up.
DISCUSSION
As two separate groups reported somatic mutations of the EGFR
TK domain in NSCLC in May 2004 (Lynch et al, 2004; Paez et al,
2004), over 15 studies on mutational analysis of this domain
(exons 18–21) in over 3000 patients have been reported by
different groups around the world (Chan et al, 2006). The
collective data indicate an overall mutation rate of 17%, but this
was higher in East Asians, never-smokers, women, and patients
with adenocarcinoma. Notably, patients with mutated EGFR had a
much higher RR to gefitinib than those with wild-type EGFR (77 vs
23%). Several groups also reported prolonged time to progression
(range, 7.6–21.7 months) and OS time (range, 13.0–30.5 months)
in patients with EGFR mutations (Chou et al, 2005; Cortes-Funes
et al, 2005; Han et al, 2005; Kim et al, 2005; Mitsudomi et al, 2005;
Table 3 Patients with EGFR mutation who were enrolled in the phase II trial
No. Age Sex
Smoking
history Histology Stage Specimen
EGFR
mutation site
Nucleotide
change
Amino-acid
change Response
TTP
(month)
OS
(month)
1 47 F Never Ad IV Surgery Exon 19 2235–2249 del del E746-A750 CR 16.8+
a 16.8+
2 72 F Never Ad Recurrence TBB Exon 19 2237–2254 del del E746-S752insV CR 8.3 14.8+
3 68 F Never Ad IV LB Exon 19 2236–2250 del del E746-A750 PR 7.5 14.7+
4 63 F Former Sq IV TBB Exon 19 2236–2250 del del E746-A750 PD 0.5 6.9
5 80 F Never Ad IV TBB Exon 19 2236–2250 del del E746-A750 SD 8.9 13.6+
6 78 M Current Ad Recurrence Surgery Exon 21 2573 T4G L858R PR 13.4+ 13.4+
7 67 F Never Ad IIIb TBB Exon 19 2236–2250 del del E746-A750 PR 12.8+ 12.8+
8 65 F Never Ad IV TBB Exon 19 2240–2257 del del L747-P753insS PR 11.9 11.9+
9 51 F Never Ad IV TBB Exon 19 2240–2257 del del L747-P753insS PR 11.3 12.7+
10 57 F Never Ad IV TBB Exon 19 2240–2257 del del L747-P753insS PR 12.7+ 12.7+
11 83 F Never Ad Recurrence Surgery Exon 21 2573 T4G L858R PR 11.7+ 11.7+
12 81 F Never Ad IIIb TBB Exon 19 2240–2257 del del L747-P753insS PR 2.6 7.5+
13 52 F Never Ad IV TBB Exon 19 2235–2249 del del E746-A750 PR 7.1 7.1+
14 70 M Never Ad IV Surgery Exon 21 2573 T4G L858R PD 1.9 3.1
15 69 F Never Ad Recurrence Surgery Exon 19 2236–2250 del del E746-A750 PR 7.0+ 7.0+
16 65 M Current Ad IV PLB Exon 19 2236–2250 del del E746-A750 PD 0.9 5.4+
Abbreviations: TTP¼time to progression; OS¼overall survival; F¼female; M¼male; Ad¼adenocarcinoma; del¼deletion; Sq¼squamous cell carcinoma; TBB¼transbron-
chial biopsy; ins¼insertion; CR¼complete remission; LB¼liver biopsy; PR¼partial remission; SD¼stable disease; PD¼progressive disease; PLB¼percutaneous lung biopsy;
EGFR¼epidermal growth factor receptor.
aStill alive with no progression at the time of data collection.
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Figure 1 (A) Overall survival and (B) PFS of all eligible patients (n¼16) were calculated according to the Kaplan–Meier method. Median survival time
has not yet been reached and median PFS was 8.9 months (95% CI, 6.7–11.1 months).
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sTakano et al, 2005; Taron et al, 2005; Zhang et al, 2005). However,
retrospective analysis of the mutation status of patients enrolled in
the previous large clinical trials of EGFR-TKI (Bell et al, 2005;
Eberhard et al, 2005; Tsao et al, 2005) has not demonstrated a
significant relationship between presence of EFGR mutation and
response to such agents. Hence, to elucidate the efficacy of
gefitinib in patients with EGFR mutations, the present prospective
trial is warranted.
In this phase II trial, we demonstrated an extremely high
objective RR of 75% (95% CI, 48–93%), median PFS of 8.9 months,
and unattained OS, consistent with previous retrospective
analyses. These results were much better than those for standard
platinum-containing regimens as first-line therapy (Schiller et al,
2002). Therefore, although the real survival benefit needs to be
examined in future randomised phase III trials, our results clearly
demonstrated that gefitinib has considerable activity in patients
with EGFR mutation, even as first-line therapy.
Despite such a good response to gefitinib, retrospective analysis
of INTACT trials shows that patients with EGFR mutation also
tend to be more sensitive to platinum-based chemotherapy than
those with wild-type EGFR (Bell et al, 2005). This matter also needs
to be addressed in future randomised phase III trials.
To date, two phase II clinical trials of gefitinib monotherapy as
first-line therapy have been performed that did not consider EGFR
mutation status. One evaluated gefitinib treatment without any
patient selection (Niho et al, 2006) and the other was conducted
with never-smokers (Lee et al, 2005). Although the former showed
an unimpressive RR of 30%, the latter demonstrated high gefitinib
efficacy; objective response, median PFS, and 1-year survival were
69%, 33 weeks and 73%, respectively. Although their observed
responses were favourable and close to those observed in the
present trial, patient selection based on smoking history might
have the disadvantage of excluding the smokers with EGFR
mutations who could have the same sensitivity to gefitinib as
never-smokers.
Toxicity observed in the present trial was mostly favourable
when compared to previous clinical trials of gefitinib (Fukuoka
et al, 2003; Kris et al, 2003; Giaccone et al, 2004; Herbst et al, 2004;
Thatcher et al, 2005) and of standard chemotherapeutic regimens
(Schiller et al, 2002). Interstitial lung disease is the most
problematic toxicity in gefitinib treatment in Japan where an
incidence of 3.5% and a fatality rate of 1.6% have been reported
(Inoue et al, 2003; Ando et al, 2006). Accordingly, in the present
trial, we planned to conduct biweekly chest CT for early detection
of ILD during the initial treatment period. Despite one case of ILD
that occurred in the present trial, the initial biweekly CT detected
asymptomatic grade 1 ILD better than has been reported
previously. As ILD was detected at an early stage, it may have
responded to discontinuation of gefitinib.
One problem related to patient selection based on mutation
status is the method of detecting EGFR mutations. In the present
trial, we used a direct sequence method with paraffin-embedded
Table 4 Major toxicities associated with gefitinib treatment
No. patients (%)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Haematologic toxicity
Leucopenia 0 (0) 1 (6) 0 (0) 0 (0)
Neutropenia 1 (6) 0 (0) 0 (0) 0 (0)
Anaemia 2 (13) 0 (0) 0 (0) 1 (6)
Thrombocytopenia 0 (0) 0 (0) 0 (0) 0 (0)
Nonhaematologic toxicity
Rash 2 (13) 5 (31) 1 (6) 0 (0)
Dry skin 4 (25) 0 (0) 0 (0) 0 (0)
Pruritus 6 (38) 0 (0) 0 (0) 0 (0)
Nail changes 0 (0) 1 (6) 0 (0) 0 (0)
Stomatitis 2 (13) 1 (6) 0 (0) 0 (0)
Gastric ulcer 0 (0) 0 (0) 1 (6) 0 (0)
Anorexia 4 (25) 1 (6) 1 (6) 0 (0)
Nausea 1 (6) 1 (6) 1 (6) 0 (0)
Vomiting 0 (0) 1 (6) 0 (0) 0 (0)
Diarrhoea 6 (38) 1 (6) 0 (0) 0 (0)
Constipation 2 (13) 0 (0) 0 (0) 0 (0)
Elevated bilirubin 2 (13) 1 (6) 0 (0) 0 (0)
Elevated AST/ALT 3 (19) 2 (13) 2 (13) 0 (0)
Elevated ALP 4 (25) 1 (6) 0 (0) 0 (0)
Elevated creatinine 2 (13) 0 (0) 0 (0) 0 (0)
ILD 1 (6) 0 (0) 0 (0) 0 (0)
Abbreviations: ILD¼interstitial lung disease; ALP¼alkaline phosphatase; AST/
ALT¼aspartate aminotransferase/alanine aminotransferase.
Figure 2 Chest X-ray (A) and CT (B) on day 30 in the patient who developed ILD. Interstitial lung disease was hardly recognisable on chest X-ray,
whereas chest CT revealed a patchy, ground-glass opacity with centrilobular distribution throughout the whole lung.
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stissues. This method is conventional but is complex, expensive,
and time consuming for daily clinical practice. Recently,
simple, sensitive, and rapid detection methods such as PNA-LNA
clump and LightCycler PCR assay have been developed
(Nagai et al, 2005; Sasaki et al, 2005) and could resolve such
problems. Clinical trials using these methods are being conducted
by multiple groups.
In conclusion, gefitinib treatment as first-line therapy for
advanced NSCLC with EGFR mutations demonstrated promising
activity and a good toxicity profile. Randomised phase III trials
comparing gefitinib and standard platinum-based chemotherapy
for patients with EGFR mutations are now being conducted and
have the potential to change our daily clinical practice with respect
to advanced NSCLC.
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